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jectives include comparing and characterizing number
and type of infections, mortality at day 100 post-trans-
plant, and hospitalizations for infectious causes in the ﬁrst
100 days of transplant. Additionally, the emergence of
resistance with quinolone and cephalosporin resistant
isolates and number of multi-drug resistant (MDR) in-
fections are characterized.
Results: A total of 80 patients were evaluated (40 levo-
ﬂoxacin, 40 cefpodoxime). Both levoﬂoxacin and cefpo-
doxime groups had similar median age, underlying
malignancy, stem cell source and transplant type. In the
levoﬂoxacin group, 70% of patients received myeloablative
conditioning versus 83% in the cefpodoxime group. Median
antimicrobial prophylaxis days were 10 versus 12 days for
levoﬂoxacin and cefpodoxime respectively. For levo-
ﬂoxacin and cefpodoxime groups respectively, neutropenic
fever occurred in 27 patients (68%) vs. 22 patients (55%),
with antibiotic escalation occurring in 93% and 92% of pa-
tients with neutropenic fever. In those patients requiring
antibiotic escalation, 60% and 52% of patients had positive
cultures in levoﬂoxacin versus cefpodoxime groups,
respectively. There were similar incidences of C. difﬁcile
and MDR infections among both levoﬂoxacin and cefpo-
doxime groups. However, higher rates of extended spec-
trum beta-lactamase-producing E. coli infections were
observed in the cefpodoxime group and higher rates of
methicillin-resistant Staphylococcus aureus infections were
noted in the levoﬂoxacin group. Rates of infections, hos-
pitalizations, and mortality in the ﬁrst 100 days were
similar among both groups.
Conclusion: Though this chart reviewwas limited by a small
sample size, similar rates of antibiotic prophylaxis failure
were demonstrated with the levoﬂoxacin and cefpodoxime
groups. Cefpodoxime can be considered as an alternative to
levoﬂoxacin for antibiotic prophylaxis in allogeneic stem cell
transplant patients.540
Voriconazole Therapeutic Drug Monitoring in a Pediatric
Hematopoietic Stem Cell Transplant Center
Abby Kim 1, Joshua Elder 1, Alexandra Cheerva 2,
Kenneth Lucas 2. 1 Pharmacy, Kosair Children’s Hospital,
Louisville, KY; 2 Pediatric Hematology/Oncology/Stem Cell
Transplant, University of Louisville, Louisville, KY
Invasive fungal infections remain one of the most serious
complications of hematopoietic stem cell transplantation,
occurring in 10-20% of recipients, with mortality rates
exceeding 50%. The epidemiology of invasive fungal in-
fections has changed in recent decades requiring changes in
drug therapy for both prophylaxis and treatment.
Voriconazole, a triazole antifungal with mold coverage, is
being used more widely due to this changing epidemiology
which has resulted in the need for more frequent therapeutic
drug monitoring to evaluate efﬁcacy and safety.
The Infectious Disease Society of America recommends
therapeutic drug monitoring of voriconazole secondary to
the known wide inter- and intra-patient variability and ge-
netic polymorphisms. It has been previously demonstrated
that voriconazole follows linear pharmacokinetics in pedi-
atric patients at doses less than 7 mg/kg, however current
increased dosing recommendations exceed this dose. In
addition, increased doses may increase the risk of adverse
effects including hepatic enzyme alteration and central
nervous system effects. These clinical practice changes
further advocate for therapeutic drug monitoring.Pediatric dosing recommendations for voriconazole were
recently increased based on the inability to reach thera-
peutic drug concentrations between the recommended
range of 1-6 mCg/mL, particularly in patients less than 2
years of age. Based on these studies and recommendations,
dosing strategies at our institution were updated to 9 mg/
kg twice daily to a maximum dose of 350 mg in patients
less than 12 years of age and 6 mg/kg twice daily to a
maximum dose of 400 mg for 2 doses followed by 4 mg/kg
twice daily to a maximum dose of 200 mg for patients
greater than or equal to 12 years of age. Of the thirteen
voriconazole levels collected, 23% were within goal range,
23% were above goal range, and 54% were below goal
range. None of the patients experienced hepatic enzyme
elevations or central nervous system effects causing
discontinuation of voriconazole. The small number of pa-
tients within goal range supports the inter- and intra-pa-
tient variability previously reported. For this reason, close
evaluation of voriconazole levels and genetic poly-
morphism testing prior to initiation is warranted.541
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Thiotepa-containing conditioning regimens remain standard
of care for certain malignancies in several pediatric hema-
topoetic stem cell transplant centers. Most commonly, thio-
tepa containing regimens are utilized in autologous
preparative regimens for central nervous system tumors;
however, it has also been utilized in regimens for neuro-
blastoma. These two diagnoses are among the most common
diagnoses for autologous stem cell transplantation in our
institution. Currently there is only one manufacturer of
thiotepa, which has resulted in marked price increases over
the past several years. Typical drug cost for thiotepa can
exceed $100,000 for the conditioning regimen of one
adolescent. Thiotepa costs have exceeded $285,000 for 5
patients over the course of the past 24 months at our single
institution.
The rise in thiotepa costs has resulted in a need to further
evaluate alternative conditioning regimens. Pediatric data
exists to support the use of conditioning regimens such as
busulfan/melphalan and carboplatin/etoposide/melphalan
in other pediatric oncologic disease states. There remains a
need for more robust clinical trial data comparing the efﬁ-
cacy and safety between these alternative conditioning reg-
imens to further determine if there is true beneﬁt of a
thiotepa-containing conditioning regimen.
As data remains lacking on the superiority of a certain pre-
parative regimen for pediatric oncologic disease states such
as central nervous system tumors, it is imperative to assess
the potential pharmacoeconomic impact of utilizing non-
thiotepa containing regimens. When comparing condition-
ing regimens, drug cost would be $109,378 for a thiotepa/
cyclophosphamide regimen in a patient with a body surface
area of 2 m2. Comparatively, a conditioning regimen of
cyclophosphamide/etoposide/melphalan would cost $9,825
in a patient with a BSA of 2m2. A thiotepa/cyclophosphamide
regimen roughly costs ten times the cost of cyclophospha-
mide/etoposide/melphalan and three times the cost of a
busulfan/melphalan containing regimen. The opportunity to
